Global Metachromatic Leukodystrophy Treatment 麻豆原创 Research Report 2024

Publication ID:

PB505242094

Publication Date:

May 27, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty.Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning.This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.
The global Metachromatic Leukodystrophy Treatment market was valued at US$ 203 million in 2023 and is anticipated to reach US$ 259.9 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Metachromatic Leukodystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metachromatic Leukodystrophy Treatment.
Report Scope
The Metachromatic Leukodystrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metachromatic Leukodystrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metachromatic Leukodystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio
Segment by Type
Tablet
Capsule
Others
Segment by Application
Hospital
Clinic
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metachromatic Leukodystrophy Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablet
1.2.3 Capsule
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laboratory
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Perspective (2019-2030)
2.2 Metachromatic Leukodystrophy Treatment Growth Trends by Region
2.2.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metachromatic Leukodystrophy Treatment Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Metachromatic Leukodystrophy Treatment Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Metachromatic Leukodystrophy Treatment 麻豆原创 Dynamics
2.3.1 Metachromatic Leukodystrophy Treatment Industry Trends
2.3.2 Metachromatic Leukodystrophy Treatment 麻豆原创 Drivers
2.3.3 Metachromatic Leukodystrophy Treatment 麻豆原创 Challenges
2.3.4 Metachromatic Leukodystrophy Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metachromatic Leukodystrophy Treatment Players by Revenue
3.1.1 Global Top Metachromatic Leukodystrophy Treatment Players by Revenue (2019-2024)
3.1.2 Global Metachromatic Leukodystrophy Treatment Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metachromatic Leukodystrophy Treatment Revenue
3.4 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Metachromatic Leukodystrophy Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy Treatment Revenue in 2023
3.5 Metachromatic Leukodystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Metachromatic Leukodystrophy Treatment Product Solution and Service
3.7 Date of Enter into Metachromatic Leukodystrophy Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Metachromatic Leukodystrophy Treatment Breakdown Data by Type
4.1 Global Metachromatic Leukodystrophy Treatment Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Metachromatic Leukodystrophy Treatment Forecasted 麻豆原创 Size by Type (2025-2030)
5 Metachromatic Leukodystrophy Treatment Breakdown Data by Application
5.1 Global Metachromatic Leukodystrophy Treatment Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Metachromatic Leukodystrophy Treatment Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2019-2030)
6.2 North America Metachromatic Leukodystrophy Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2019-2024)
6.4 North America Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2019-2030)
7.2 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2019-2024)
7.4 Europe Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Metachromatic Leukodystrophy Treatment 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2019-2030)
9.2 Latin America Metachromatic Leukodystrophy Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Metachromatic Leukodystrophy Treatment 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ArmaGen, Inc.
11.1.1 ArmaGen, Inc. Company Detail
11.1.2 ArmaGen, Inc. Business Overview
11.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.1.4 ArmaGen, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.1.5 ArmaGen, Inc. Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Detail
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Recursion Pharmaceuticals, Inc.
11.3.1 Recursion Pharmaceuticals, Inc. Company Detail
11.3.2 Recursion Pharmaceuticals, Inc. Business Overview
11.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.3.4 Recursion Pharmaceuticals, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.3.5 Recursion Pharmaceuticals, Inc. Recent Development
11.4 RegenxBio, Inc.
11.4.1 RegenxBio, Inc. Company Detail
11.4.2 RegenxBio, Inc. Business Overview
11.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.4.4 RegenxBio, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.4.5 RegenxBio, Inc. Recent Development
11.5 Takeda Pharmaceutical Company Limited
11.5.1 Takeda Pharmaceutical Company Limited Company Detail
11.5.2 Takeda Pharmaceutical Company Limited Business Overview
11.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Introduction
11.5.4 Takeda Pharmaceutical Company Limited Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.5.5 Takeda Pharmaceutical Company Limited Recent Development
11.6 Orchard Therapeutics Plc
11.6.1 Orchard Therapeutics Plc Company Detail
11.6.2 Orchard Therapeutics Plc Business Overview
11.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Introduction
11.6.4 Orchard Therapeutics Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.6.5 Orchard Therapeutics Plc Recent Development
11.7 Magenta Therapeutics
11.7.1 Magenta Therapeutics Company Detail
11.7.2 Magenta Therapeutics Business Overview
11.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.7.4 Magenta Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.7.5 Magenta Therapeutics Recent Development
11.8 Shire Plc
11.8.1 Shire Plc Company Detail
11.8.2 Shire Plc Business Overview
11.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Introduction
11.8.4 Shire Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.8.5 Shire Plc Recent Development
11.9 Oxyrane
11.9.1 Oxyrane Company Detail
11.9.2 Oxyrane Business Overview
11.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Introduction
11.9.4 Oxyrane Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.9.5 Oxyrane Recent Development
11.10 NanoMedSyn
11.10.1 NanoMedSyn Company Detail
11.10.2 NanoMedSyn Business Overview
11.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Introduction
11.10.4 NanoMedSyn Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.10.5 NanoMedSyn Recent Development
11.11 Juventas Therapeutics
11.11.1 Juventas Therapeutics Company Detail
11.11.2 Juventas Therapeutics Business Overview
11.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.11.4 Juventas Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.11.5 Juventas Therapeutics Recent Development
11.12 GenSight Biologics
11.12.1 GenSight Biologics Company Detail
11.12.2 GenSight Biologics Business Overview
11.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Introduction
11.12.4 GenSight Biologics Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.12.5 GenSight Biologics Recent Development
11.13 Inozyme Pharma
11.13.1 Inozyme Pharma Company Detail
11.13.2 Inozyme Pharma Business Overview
11.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Introduction
11.13.4 Inozyme Pharma Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.13.5 Inozyme Pharma Recent Development
11.14 ONL Therapeutics
11.14.1 ONL Therapeutics Company Detail
11.14.2 ONL Therapeutics Business Overview
11.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.14.4 ONL Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.14.5 ONL Therapeutics Recent Development
11.15 AngioChem
11.15.1 AngioChem Company Detail
11.15.2 AngioChem Business Overview
11.15.3 AngioChem Metachromatic Leukodystrophy Treatment Introduction
11.15.4 AngioChem Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.15.5 AngioChem Recent Development
11.16 Cabaletta Bio
11.16.1 Cabaletta Bio Company Detail
11.16.2 Cabaletta Bio Business Overview
11.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Introduction
11.16.4 Cabaletta Bio Revenue in Metachromatic Leukodystrophy Treatment Business (2019-2024)
11.16.5 Cabaletta Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.